Диссертация (1141348), страница 14
Текст из файла (страница 14)
675 p.57D.F.V. Lewis et al. Cytochrome P450 Substrate Specifities,Substrate structural Templates and Enzyme Active Site Geometries // Drugmetabolism and drug interctions. 1999. V.15. P.151.58B. Zhu et al. Assessment of cytochrome P450 activity by a five-drugcocktail approach // Journal of Clinical Pharmacy and Therapeutics. 2001V.70(5). P.61.59M. Christensen et al. The Karolinska cocktail for phenotyping offive human cytochrome P450 enzymes // Journal of Clinical Pharmacy andTherapeutics. 2003. V.73.
P.517–528.60S. Chainuvati et al. Combined phenotypic assessment of cytochromeP450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidaseactivities with the ‘‘Coopers- town 5 + 1 cocktail’’ // Journal of ClinicalPharmacy and Therapeutics. 2003. V.74. P.437–447.61O.Q. Yin et al. Rapid determination of five probe drugs and theirmetabolites in human plasma and urine by liquid chromatography/tandem massspectrometry: application to cytochrome P450 phenotyping studies // RapidCommunications in Mass Spectrometry. 2004. V.18. P.2921–2933.62N.K. Zgheib et al. Validation of incorporating flurbiprofen into thePittsburgh cocktail // Journal of Clinical Pharmacy and Therapeutics. 2006. V.80.V.257–263.63J.Y. Ryu et al.
Development of the ‘‘Inje cocktail’’ for high-throughput evaluation of five human cytochrome P450 isoforms in vivo // Journalof Clinical Pharmacy and Therapeutics. 2007. V.82. P.531–540.64K.S. Oh et al. High-sensitivity liquid chromatography-tandem massspectrometry for the simultaneous determination of five drugs and their112cytochrome P450-specific probe metabolites in human plasma // Journal ofChromatography B, Analytical technologies in the biomedical and life sciences.2012. V.1 P.56-64.65S. Ghassabianet et al.
A high-throughput assay using liquidchromatography-tandem mass spectrometry for simultaneous in vivo phenotypingof 5 major cytochrome p450 enzymes in patients // Therapeutic Drug Monitoring.2009 V.31(2). P.239-46.66Tanaka S. et al. Simultaneous LC-MS/MS analysis of the plasmaconcentrations of a cocktail of 5 cytochrome P450 substrate drugs and theirmetabolites. Biol Pharm Bull. 2014;37(1):18-25.67В.В. Смирнов.
Разработка методики определения кортизола и 6-бета-гидроксикортизолавмочесцельюустановленияактивностиизофермента CYP 3A4. диссертация на соискание ученой степени кандидатафармацевтическихнаук–М.:ГОУВПО"Московскаямедицинскаяакадемия". 2011. 95 с.68В.В. Смирнов, А.Ю. Савченко, Г.В. Раменская. Разработка ивалидация методики количественного определения эндогенного кортизола и6-β-гидроксикортизолавмочесцельюопределенияактивностиизофермента CYP 3A4 // Биомедицина.
2010. Т. 1. № 4. С. 56-60.69Ainslie GR, Wolf KK, Li Y et al. Assessment of a candidate markerconstituent predictive of a dietary substance-drug interaction: case study withgrapefruit juice and CYP3A4 drug substrates. // The Journal of Pharmacologyand experimental theurapeutics. 2014. Vol.351(3). P.576-58470Tomalik-Scharte D1, Lütjohann D, Doroshyenko O et al.
Plasma4beta-hydroxycholesterol:anendogenousCYP3Ametric?//Clinicaletal.pharmacology and theurapeutics. 2009. V.86(2). P.147-153.71deGraanAJ,SparreboomA,deBruijnP4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treatedwith taxanes // British journal of clinical pharmacology. 2015. V.(3). P.560-568.11372Rettie AE, et al. Clinical and toxicological relevance of CYP2C9:drug-drug interactions and pharmacogenetics // Annual Review of Pharmacologyand Toxicology. 2005. V.45: 477–94.73Bing Zhu et al. Assessment of cytochrome P450 activity by a five-drug cocktail approach // Pharmacokinetics and Drug Disposition. 2001. V. 70(5).P.
455-46174Kyung-Suk Oh et al. High-sensitivity liquid chromatography–tandem mass spectrometry for the simultaneous determination of five drugs andtheir cytochrome P450-specific probe metabolites in human plasma // Journal ofChromatography B. 2012.
V.895. P.56-6475Кукес В.Г., Фисенко В.П., Стародубцев А.К., Раменская Г.В.,Сычев Д.А., Андреев Д.А., Рейхарт Д.В. Метаболизм лекарственныхпрепаратов под ред. Академика РМН, проф. Кукеса В.Г., чл.-корр. РАМН,проф. Фисенко В.П. / М.: Палея М, 2004.76Goodman & Gilman’s: The Pharmacological basis of theurapeutics,Twelfth Edition. / New-York, McGraw-Hill. 2011. 2084 P.77Thomas F. Woolf. Handbook of drug metabolism / CRC Press,1999. 612 P.78Cytochrome P450: structure, mechanism and biochemistry / editedby Paul R.
Ortiz de Montellano. – 3rd ed. Kluwer Academic/Plenum Publishers,New York, 2005. 689 P.79Phillips, I.R., Shephard E.A., Ortiz de Montellano, P.R. CytochromeP450 Protocols / Humana Press, 2013. 315 P.80Р.Х. Абдрашитов, А.Е. Петухов, В.В. Смирнов. Разработка ивалидация биоаналитической методики количественного определенияпинолина и его метаболита 6-гидрокси-1,2,3,4-тетрагидро-бета-карболина сцелью определения активности изофермента CYP2D6 // Разработка ирегистрация лекарственных средств. 2016.
№14 (1). С. 190-195.11481G.R. Wilkinson . Drug metabolism and variability among patients indrug response // The New England Journal of Medicine. 2005. V.352(21)P.2211–2221.82K.N. Kanebratt et al. Cytochrome P450 induction by rifampicin inhealthy subjects: determination using the Karolinska cocktail and the endogenousCYP3A4 marker 4beta-hydroxycholesterol // Clinical Pharmacology &Therapeutics. 2008. V.84(5). P.589–594.83N.
Inui et al. Chronological effects of rifampicin discontinuation oncytochrome P450 activity in healthy Japanese volunteers, using the cocktailmethod. Clin Pharmacol Ther. 2013;94(6):702–884M.Bosilkovska et al. Geneva cocktail for cytochrome P450 and P-glycoprotein activity assessment using dried blood spots // Clinical Pharmacology& Therapeutics. 2014.
V.96(3). P.349–35985R.A. Brench et al. In vivo modulation of CYP enzymes by quinidineand rifampin // Clinical Pharmacology & Therapeutics. 2000. V.68(4). P.401–41186L.M. Vesse et al. CYP2B6 mediates the in vitro hydroxylation ofbupropion: potential drug interactions with other antidepressants // DrugMetabolism & Disposition. 2000. V.28(10). P.1176–1183.87C.F. Thorn et al. PharmGKB summary: very importantpharmacogene information for CYP1A2 // Pharmacogenetetics & Genomics.2012. V.22(1). P.73–7788D. Van Booven et al. Cytochrome P450 2C9-CYP2C9 //Pharmacogenetetics & Genomics. 2010.
V.20(4). P.277–281.89R.P. Owen et al. Cytochrome P450 2D6 // Pharmacogenetetics &Genomics. 2009. V.19(7). P.559–562.90S.M. de Morais et al. The major genetic defect responsible for thepolymorphism of S-mephenytoin metabolism in humans // Journal of BiologicalChemistry. 1994. V.269(22). P.15419–1542291B. Link et al. Pharmacokinetics of intravenous and oral midazolamin plasma and saliva in humans: usefulness of saliva as matrix for CYP3A115phenotyping // British Journal of Clinical Pharmacology. 2008.
V.66(4). P.473–84.92Y. Caraco et al. Phenytoin metabolic ratio: a putative marker ofCYP2C9 activity in vivo // Pharmacogenetics. 2001. V.11(7). P.587–596.93J.M.Maglich et al. Nuclear pregnane x receptor and constitutiveandrostane receptor regulate overlapping but distinct sets of genes involved inxenobiotic detoxification // Molecular Pharmacology. 2002. V.62(3). P.638–646.94J.T. Backman et al. Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine andcaffeine // European Journal of Clinical Pharmacology. 2006. V.62(6).
P.451–461.95U. Yasar et al. Intra-individual variability in urinary losartanoxidation ratio, an in vivo marker of CYP2C9 activity // British Journal ofClinical Pharmacology. 2002. V.54(2). P.183–18596U. Yasar et al. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype // Clinical Pharmacology &Therapeutics. 2002. V.71(1). P.89–98.97A.
Derungs et al. Effects of Cytochrome P450 Inhibition andInduction on the Phenotyping Metrics of the Basel Cocktail: A RandomizedCrossover Study // Clinical Pharmacokinetics. 2015. Vol.55(1). P.79-91.98Donzelli M. et al. The basel cocktail for simultaneous phenotypingof human cytochrome P450 isoforms in plasma, saliva and dried blood spots //Clinical Pharmacokinetics. 2014. Vol.53(3).
P.271-282.99DeAndrésF.Evaluationofdrug-metabolizingenzymehydroxylation phenotypes in Hispanic populations: the CEIBA cocktail // DrugMetabolism and Drug Interactions. 2013. Vol.28(3). P.135-146.100Bosilovska M. Evaluation of Mutual Drug-Drug Interaction withinGeneva Cocktail for Cytochrome P450 Phenotyping using Innovative DriedBlood Sampling Method // Basic & Clinical Pharmacology & Toxicology. 2016.Vol. 199(3). P.284-290.116101Zhou SF. Polymorphism of human cytochrome P450 2D6 and itsclinical significance: Part I // Clinical Pharmacokinetics.
2009. V.48(11). P.689723.102Хубутия М.Ш., Чжао А.В., Джаграев К.Р. Трансплантацияпечени как радикальный метод лечения конечных стадий заболеванийпечени // Хирургия. 2010. 8(47). С. 13-19103Шевченко О.П., Цирульникова О.М., Бугров А.В.Инсулиноподобный фактор роста-1 при трансплантации печени детям сврожденными и наследственными заболеваниями гепатобилиарной системы// Вестник трансплантологии и искуственных органов.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
